Current status of fertility preservation in a Spanish tertiary public hospital: multidisciplinary approach and experience in over 1500 patients

Clin Transl Oncol. 2024 May;26(5):1129-1138. doi: 10.1007/s12094-023-03330-2. Epub 2023 Oct 23.

Abstract

Purpose: Currently, 15% of gynaecological and 9% of haematological malignancies are diagnosed before the age of 40. The increased survival rates of cancer patients who are candidates for gonadotoxic treatments, the delay in childbearing to older ages, and the optimization of in vitro fertilisation techniques have all contributed to an increased interest in fertility preservation (FP) treatments. This study reviews the experience of the Fertility Preservation Programme (FPP) of a tertiary public hospital with a multidisciplinary approach.

Methods: This retrospective study included all the available (FP) treatments, performed in patients of childbearing age between 2006 and 2022.

Results: 1556 patients were referred to the FPP: 332 oocyte vitrification cycles, 115 ovarian cortex cryopreservation with 11 orthotopic autotransplantations, 175 gonadotropin-releasing hormone (GnRH) agonist treatments, 109 fertility-sparing treatments for gynaecological cancer, and 576 sperm cryopreservation were performed. Malignancy was the main indication for FP (the main indications being breast cancer in women and haematological malignancies in men), although non-oncological pathologies, such as endometriosis and autoimmune diseases, have increased in recent years. Currently, the most widely used FP technique is oocyte vitrification, the increase of which has been associated with a decrease in the use of cortex CP and GnRH agonists.

Conclusions: The increase in FP treatment reflects the implementation of reproductive counselling in oncology programmes. A multidisciplinary approach in a tertiary public hospital allows individualised FP treatment for each patient. In recent years, there has been a change in trend with the introduction of new indications for FP and a change in techniques due to their optimisation.

Keywords: Fertility preservation; Gynecological malignancies; Oncological patients; Oocyte vitrification; Ovarian cortex cryopreservation; Sperm cryopreservation.

MeSH terms

  • Breast Neoplasms*
  • Female
  • Fertility Preservation*
  • Gonadotropin-Releasing Hormone
  • Hematologic Neoplasms* / therapy
  • Humans
  • Male
  • Retrospective Studies
  • Semen

Substances

  • Gonadotropin-Releasing Hormone